Dopamine Transporter Imaging in Parkinson Disease: Progressive Changes and Therapeutic Modification after Anti-parkinsonian Medications
作者： Ken Ikeda , Junya Ebina , Kiyokazu Kawabe , Yasuo Iwasaki
DOI: 10.2169/INTERNALMEDICINE.2489-18
关键词:
摘要: Parkinson disease (PD) is a slowly progressive neurodegenerative characterized by the loss of dopaminergic neurons and terminals in nigrostriatal system. Dopamine transporter (DAT) imaging widely performed for differential diagnosis PD other degenerative parkinsonism from essential tremor, vascular parkinsonism, drug-induced parkinsonism. DAT plasma membrane carrier specific to dopamine that are responsible re-uptaking synaptic cleft back into nerve ending. binding might reflect striatal presynaptic dysfunction or expression patients. Longitudinal studies have reported changes early This may be used as biomarker. Follow-up therapeutic interventions has been applied several anti-parkinsonian drugs. We herein review modification anti-PD medications
sci-hub.se 参考文章(43)
Levodopa and the progression of Parkinson's disease. The New England Journal of Medicine. ,vol. 351, pp. 2498- 2508 ,(2004) , 10.1056/NEJMOA033447
Julia Kraemmer, Gabor G. Kovacs, Laura Perju-Dumbrava, Susanne Pirker, Tatiana Traub-Weidinger, Walter Pirker, Correlation of striatal dopamine transporter imaging with post mortem substantia nigra cell counts. Movement Disorders. ,vol. 29, pp. 1767- 1773 ,(2014) , 10.1002/MDS.25975
Walter Pirker, Iris Holler, Willibald Gerschlager, Susanne Asenbaum, Georg Zettinig, Thomas Brücke, Measuring the rate of progression of Parkinson's disease over a 5-year period with β-CIT SPECT Movement Disorders. ,vol. 18, pp. 1266- 1272 ,(2003) , 10.1002/MDS.10531
Walter Pirker, Schiva Djamshidian, Susanne Asenbaum, Willibald Gerschlager, Gotthard Tribl, Martha Hoffmann, Thomas Brücke, Progression of dopaminergic degeneration in Parkinson's disease and atypical parkinsonism: A longitudinal β-CIT SPECT study Movement Disorders. ,vol. 17, pp. 45- 53 ,(2002) , 10.1002/MDS.1265
Elina Nurmi, Jörgen Bergman, Olli Eskola, Olof Solin, Susanna M. Hinkka, Pirkko Sonninen, Juha O. Rinne, Reproducibility and effect of levodopa on dopamine transporter function measurements: a [18F]CFT PET study. Journal of Cerebral Blood Flow and Metabolism. ,vol. 20, pp. 1604- 1609 ,(2000) , 10.1097/00004647-200011000-00010
Sean J. Colloby, E. David Williams, David J. Burn, Jim J. Lloyd, Ian G. McKeith, John T. O’Brien, Progression of dopaminergic degeneration in dementia with Lewy bodies and Parkinson's disease with and without dementia assessed using 123I-FP-CIT SPECT. European Journal of Nuclear Medicine and Molecular Imaging. ,vol. 32, pp. 1176- 1185 ,(2005) , 10.1007/S00259-005-1830-Z
Ken Ikeda, Sayori Hanashiro, Masahiro Sawada, Yasuo Iwasaki, Preliminary study of zonisamide monotherapy in de novo patients with early Parkinson's disease Neurology and Clinical Neuroscience. ,vol. 3, pp. 163- 166 ,(2015) , 10.1111/NCN3.179
M. Murata, K. Hasegawa, I. Kanazawa, , Zonisamide improves motor function in Parkinson disease: A randomized, double-blind study Neurology. ,vol. 68, pp. 45- 50 ,(2007) , 10.1212/01.WNL.0000250236.75053.16
Hitoshi Uno, Mikio Kurokawa, Yoshinobu Masuda, Haruki Nishimura, Studies on 3-substituted 1,2-benzisoxazole derivatives. 6. Syntheses of 3-(sulfamoylmethyl)-1,2-benzisoxazole derivatives and their anticonvulsant activities. Journal of Medicinal Chemistry. ,vol. 22, pp. 180- 183 ,(1979) , 10.1021/JM00188A011
J. Y. Hong, J. S. Oh, I. Lee, M. K. Sunwoo, J. H. Ham, J. E. Lee, Y. H. Sohn, J. S. Kim, P. H. Lee, Presynaptic dopamine depletion predicts levodopa-induced dyskinesia in de novo Parkinson disease Neurology. ,vol. 82, pp. 1597- 1604 ,(2014) , 10.1212/WNL.0000000000000385